author-photo

Pallavi Sachdev

Eisai

23

Papers

500

Citations

Citation Trend

Filter By

Papers (17) Sort By

Journal Conference Others

High response rate and durability driven by HLA genetic diversity in kidney cancer patients treated with the immunotherapy combination lenvatinib and pembrolizumab.

2021 Molecular Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers.

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (10)
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (123)
First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor.

2020 British Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (16)
Abstract 1924: Genetic analysis of responses to eribulinversusvinorelbine and paclitaxel in 100 cancer cell lines from the cancer cell line Encyclopedia (CCLE)

2020
Show All
- Source
- Cite
- Save
Citations (1)
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

2019 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (200)
994OLenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC)

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Biomarker results and preclinical rationale for combination lenvatinib and pembrolizumab in advanced endometrial carcinoma.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
76PCorrelative analyses of serum biomarkers and efficacy outcomes in the randomized phase II trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Abstract 5050: Pharmacodynamic and pharmacokinetic relationship of single agent E7449 in patients with advanced solid tumors or B-cell malignancies

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)